NEW YORK and LONDON, December 2, 2014 Celsus Therapeutics (NASDAQ: CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur …
Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been …
Celsus Therapeutics Plc Receives Approval from the Ministry of Health of Israel For Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli …
Celsus Therapeutics PLC Announces Details of Annual General Meeting of Shareholders
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today that the annual general …
Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new …
